Theralink Technologies is a molecular profiling and precision medicine oncology company specializing in patented, biomarker assay services. We use quantitative Laser Capture Microdissection (LCM) and Reverse Phase Protein Array (RPPA) technology to support therapeutic development from discovery through clinical trials. This patented technology offers Next Generation Proteomics (NGP)TM services that produce in-depth broad-scale signalling analysis from a relatively small amount of sample.  Our coverage expands every day and currently sits at 700+ proteins and phosphoproteins.

Our platform can also be used as a companion diagnostic (CDx) in the clinical setting. In fact, we have curated the Theralink Assay- a breast cancer clinical panel intended for breast cancer patients with:

  • Triple-Negative Breast Cancer- Late Stage (stage III-IV)
  • HER2+ Breast Cancer- Late Stage (stage III-IV)
  • ER+/HER2- Breast Cancer- Late Stage (stage III-IV)
  • Metastatic Breast Cancer
  • Inflammatory Breast Cancer

With 32 analytes and biomarkers of interest, we offer ~90% more targets than the typical Immunohistochemistry assay allowing us to be more predictive of the right therapy for the right patient at the right time. We already have our very first patient and it’s amazing to make an impact and improve the lives of patients!


Pathway Created with Biorender

#oncology #healthcare #research #precisionmedicine #precisiononcology #proteomics #signaling #pathways #genomics #cancer #tumor #biotech #biopharma #biotechnology #biopharmaceuticals #therapeutics #breastcancerawareness